



## Recent Developments in Cancer Biomarkers for Diagnosis and Prognosis

Guest Editor:

**Dr. Raghu Sinha**

Department of Biochemistry and  
Molecular Biology, Penn State  
College of Medicine, Hershey, PA,  
USA

Deadline for manuscript  
submissions:

**25 January 2025**

### Message from the Guest Editor

The biological molecules reflecting the state of initiation and progression in cancer are deemed important biomarkers. These molecules can be measured in tissues, plasma serum saliva, and other biological fluids. Cancer biomarkers are useful not only for early detection but also for monitoring disease progression and treatments. Measuring one biomarker may not be sufficient for all cancer types, and some cancers require a group of biomarkers for accurate diagnosis. These biomarkers could be a combination of tissue and secretory factors. This Special Issue welcomes research articles addressing recent research on experimental, pre-clinical, and clinical cancer biomarkers for diagnosis and prognosis, with a special focus on approaches for discovering novel cancer biomarkers. Biomarkers can include proteins, nucleic acids, metabolites, and more.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)